Updates are available Correction dated 2022-01-05
Click to view Correction: https://doi.org/10.1038/s41467-021-27814-3
-
Authors
Liu, Yi
Debo, Brian
Li, Mingfeng https://orcid.org/0000-0002-7959-6008
Shi, Zhennan
Sheng, Wanqiang https://orcid.org/0000-0003-1064-9594
Shi, Yang https://orcid.org/0000-0001-9713-1709
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (U01 MH116488)
Boston Children’s Hospital, Ludwig Institute for Cancer Research Oxford
- License Information
-
More Information
Article History
Received: 17 May 2020
Accepted: 3 November 2021
First Online: 24 November 2021
Change Date: 5 January 2022
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41467-021-27814-3
Competing interests
: Y.S. is a co-founder and equity holder of K36 Therapeutics, a consultant for Active Motif, and holds equity in Imago Biosciences. Y.S. is a member of the Scientific Advisory Board of the College of Life Sciences, West Lake University, and a member of the MD Anderson External Advisory Board. All other authors declare no competing interests.
